Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXELIXIS, INC.EXEL · Entity 3386 | Director | May 27, 2026 | May 29, 2026 |
| IMMUNOMEDICS INCIMMU · Entity 145732 | Director | January 08, 2017 | January 12, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXELIXIS, INC.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,487 |
Reported balance
After 2026-05-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 8,367 · Balance 29,487 F1: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date. F2: Includes 17,455 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date.
F2: Includes 17,455 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs.
IMMUNOMEDICS INC
Report date January 08, 2017 · Filed January 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.73 · Expires 2024-01-08 | Direct | 22,500 |
Reported balance
After 2017-01-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-08 · Grant · Acquired 22,500 · Balance 22,500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 29, 2026 21:43 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 8,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-26-000077 · wk-form4_1780090995.xml · nonDerivative · entry 1 Oliver Bob · CIK 0001694534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,487 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date. F2 · balance_after: Includes 17,455 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 01:48 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 9,088 | $0.00 Strike: $19.28 | $0.00 |
DisclosureSEC source: 0000939767-26-000023 · wk-form4_1771465734.xml · derivative · entry 4 Oliver Bob · CIK 0001694534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,118 Underlying: Common Stock · 9,088 shares Expires 2030-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 36,353 shares of Common Stock, became fully exercisable on May 31, 2023. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 01:48 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 21,162 | $43.90 | $929,011.80 |
DisclosureSEC source: 0000939767-26-000023 · wk-form4_1771465734.xml · nonDerivative · entry 3 Oliver Bob · CIK 0001694534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,120 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $43.90 to $43.96. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F1 · balance_after: Includes 18,900 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 01:48 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 9,088 | $43.61 | $396,327.68 |
DisclosureSEC source: 0000939767-26-000023 · wk-form4_1771465734.xml · nonDerivative · entry 2 Oliver Bob · CIK 0001694534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,282 F1 · balance_after: Includes 18,900 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 01:48 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 9,088 | $19.28 | $175,216.64 |
DisclosureSEC source: 0000939767-26-000023 · wk-form4_1771465734.xml · nonDerivative · entry 1 Oliver Bob · CIK 0001694534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 18,900 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 1,044 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-25-000138 · wk-form4_1763601062.xml · nonDerivative · entry 1 Oliver Bob · CIK 0001694534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,282 F1 · kind: On November 17, 2025, the Reporting Person gifted 1,044 shares of Exelixis, Inc. common stock ("Common Stock") to a not-for-profit organization. F2 · balance_after: Includes 18,900 shares of Common Stock that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| May 29, 2025 Filed May 30, 2025 23:14 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 9,812 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-25-000093 · wk-form4_1748646876.xml · nonDerivative · entry 1 Oliver Bob · CIK 0001694534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,326 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 29, 2026, subject to the Reporting Person's continuous service through that date. F2 · balance_after: Includes 42,282 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 15,147 | $0.00 Strike: $19.28 | $0.00 |
DisclosureSEC source: 0000939767-25-000036 · wk-form4_1740618053.xml · derivative · entry 3 Oliver Bob · CIK 0001694534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,206 Underlying: Common Stock · 15,147 shares Expires 2030-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 36,353 shares of Common Stock, became fully exercisable on May 31, 2023. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 18,647 | $37.25 | $694,600.75 |
DisclosureSEC source: 0000939767-25-000036 · wk-form4_1740618053.xml · nonDerivative · entry 2 Oliver Bob · CIK 0001694534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,514 F1 · balance_after: Includes 32,470 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,147 | $19.28 | $292,034.16 |
DisclosureSEC source: 0000939767-25-000036 · wk-form4_1740618053.xml · nonDerivative · entry 1 Oliver Bob · CIK 0001694534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 32,470 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| May 31, 2024 Filed Jun 5, 2024 00:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 18,838 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-24-000098 · wk-form4_1717546813.xml · nonDerivative · entry 1 Oliver Bob · CIK 0001694534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,014 F1 · date: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 100% of the shares subject to the RSU award on May 31, 2025, subject to the Reporting Person's continuous service through that date. F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 100% of the shares subject to the RSU award on May 31, 2025, subject to the Reporting Person's continuous service through that date. F2 · balance_after: Includes 32,470 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of RSUs. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 01:51 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 36,353 | $0.00 Strike: $19.28 | $0.00 |
DisclosureSEC source: 0000939767-23-000066 · wk-form4_1685757106.xml · derivative · entry 2 Oliver Bob · CIK 0001694534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,353 Underlying: Common Stock · 36,353 shares Expires 2030-05-30 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 01:51 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 18,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000066 · wk-form4_1685757106.xml · nonDerivative · entry 1 Oliver Bob · CIK 0001694534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,176 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on each of the first four anniversaries of the Transaction Date, subject to the Reporting Person's continuous service through such dates. F3 · balance_after: Includes 18,176 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 08, 2017 Filed Jan 12, 2017 11:57 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantStock Options (right to buy) · Derivative | 22,500 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001104659-17-002096 · a4.xml · derivative · entry 1 Oliver Bob · CIK 0001694534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock, par value $0.01 per share · 22,500 shares Expires 2024-01-08 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.